Pine Payment Solutions Sdn Bhd (PPS), a subsidiary of Pine Labs, announced a partnership with Citi Malaysia that will allow the bank’s credit cardholders to enjoy interest-free instalments.
Citi Malaysia head of cards and unsecured lending Alicia Lau said in partnership with Pine Labs, the bank aims to enable the Citi Zero Easy Pay Plan (EPP) at more than 1,000 retail stores nationwide within the next few months.
Gamuda Land will be launching the first phase of Gardens Square, comprising 19 double and three-storey shops and 19 office lots in Gamuda Gardens, Rawang in October. In a press statement, Gamuda reveals that three anchor tenants are in the pipeline, which include an established grocer occupying more than 20,000 sq ft as well as a double-storey drive-through fast food franchise.
Hospitality startup Oyo Hotels entered a multiyear alliance with Microsoft Corp. to develop new travel technologies enabled by the U.S. firm’s Azure cloud infrastructure and artificial intelligence. The work will focus on improving the digital capabilities of small and medium hotels as well as home-stays and Microsoft has made an investment in Oyo, the two companies announced on Thursday, 9 September.
Google recently stepped up their cloud collaboration tools for businesses, expecting “hybrid” work routines to remain even after the pandemic has ended. They are bridging the gap in hybrid work models by making enhancements in Google Meet and introducing Google Workspaces. “We’ve seen a radical transformation, and a lot of that transformation is here to stay,” Google product management director Dave Citron said during a briefing on new Workspace offerings.
For nearly 20 years, Novartis has broaden oncology drug access through the Glivec® International Patient Assistance Program (GIPAP) worldwide. GIPAP is one of the most innovative patient assistance programs ever implemented on a global scale. Through GIPAP, Novartis provides imatinib at no cost to eligible patients in lower-income countries where there may not be access to reimbursement or funding mechanisms and to those unable to pay for the medication. The program has served the CML treatment needs of approximately 75,000 people since its inception.
Since 2002, GIPAP has helped many Malaysian Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumor (GIST) patients to receive treatment with imatinib under the expert care of physicians. In 2008 GIPAP transitioned to the Malaysian Patient Assistance Program (MYPAP) and Novartis Oncology Access (NOA) (2012) respectively which included the 2nd generation TKI nilotinib. MYPAP program is based on a co-shared contribution model, whereby the annual treatment cost is partially covered by the Ministry of Health (MOH) and partially contributed by Novartis. To date, the programs have provided supports to more than 2,000 people living with CML and GIST.
This cost-sharing model has effectively provided universal coverage to CML and GIST patients in Malaysia for nearly a decade, and remains a unique model not being offered to any other therapeutic area. MyPAP has continued to grow from strength to strength in support of the increasing number of CML and GIST patients. It also underscores the organization’s commitment to oncology research within the country in addressing unmet needs in Malaysia, and with the focus on delivering the right treatment to the right patient, one of which is by enabling industry-leading access programs to improve availability of treatment and care. This is also in line with some of SDG17’s goals namely:
- Encourage Effective Partnerships – encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships; and
- Enhance the Global Partnership for Sustainable Development – Enhance the Global Partnership for Sustainable Development, complemented by multi-stakeholder partnerships that mobilize and share knowledge, expertise, technology and financial resources, to support the achievement of the Sustainable Development Goals in all countries, in particular developing countries.
Sime Darby Property Bhd reported today that their second quarter net profit at RM19.91 million is a significant rise compared to their net loss of RM93 million last year.
Due to aggressive online marketing, revenue rose as the real estate developer’s residential property sales improved significantly at a time when the Malaysian property sector was facing the effects of pandemic-led movement restrictions.
In a statement to Bursa Malaysia today, Sime Darby Property said revenue rose to RM502.83 million in the second quarter ended June 30, 2021 (2QFY21) from RM288.23 million.
